GlassScriptPhysician profile
Bret C Bielawski
NPI 1437149671
$4,294.40
in general payments reported to CMS, 2019-2025
31 companies · $96.08 in 2025
The $96.08 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,148 · 2020: $251 · 2021: $165 · 2022: $1,328 · 2023: $1,243 · 2024: $63.27 · 2025: $96.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,402.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $565.28 | 2019-2023 | |
| Lilly USA, LLC | $419.62 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $409.17 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $382.29 | 2019-2023 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $316.15 | 2019-2023 | Xarelto |
| Abbott Laboratories | $269.62 | 2022-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $230.70 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $205.43 | 2019-2023 | Myrbetriq |
| Abbvie INC. | $190.63 | 2019-2023 | Ubrelvy, Viberzi, Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.73 | 2019-2023 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $175.62 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $133.04 | 2022-2023 | |
| Amarin Pharma, INC. | $99.18 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $88.69 | 2019-2023 | Breztri |
| Glaxosmithkline, LLC. | $73.45 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $69.42 | 2023 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $59.17 | 2022-2023 | Krystexxa |
| Amneal Pharmaceuticals LLC | $56.10 | 2019-2023 | Unithroid |
| Sanofi-Aventis U.S. LLC | $54.03 | 2019-2022 | |
| Alvogen INC | $50.84 | 2022-2023 | Teriparatide |
| Sanofi Pasteur INC. | $40.48 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $38.68 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.83 | 2019-2023 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $31.14 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.94 | 2022 | |
| Paratek Pharmaceuticals, INC. | $18.83 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.66 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.50 | 2022 | |
| G Medical Diagnostic Services, INC. | $12.33 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.22 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bret Bielawski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.